Answer: because it would equal "billions" in market cap! Biotech always trades in multiples, and now the bashers have spotted us several hundred million in revenue and are trying to hold the line to that. Good luck!
Sentiment: Strong Buy
1. An estimated 630,000 cases of MDR-TB World-wide each year - of which 120,000 are attributed to China, which has been spending billions on health care improvement in recent years and is predicted to be spending $1 trillion annually on health care by 2020.
An injected aminoglycoside (such as amikacin) is currently equal-first in order of preference for the recommended five-drug regimen.
2. An estimated 110,000 cases of NTM in the US, Europe and Japan each year - currently treated with off-label therapies, including aminoglycoside injection.
3. An estimated 65,000 with Cystic Fibrosis in the US and Europe - for which twice-daily tobramycin inhalation solution (or powder) is currently the most widely-used antibiotic.
Six months of Arikace therapy (spread over a year for CF, or continuously for six months otherwise) has been priced by analysts at $36,000 or more.
We don't yet know if Arikace is capable of eradicating a pulmonary mycobacterial infection in less than six months.
However, $1 billion in revenue is equivalent to just 28,000 patients taking six months of therapy at that price.
And yes - the market usually values a growing biotech at five times (or greater) annual revenue.
Rbalboa22 - you'd stand more chance of convincing others that you really ARE laughing at me if you backed it up with your own prediction of peak numbers of patients treated with Arikace for MDR-TB, NTM and CF.
Without that it makes we wonder if what you're actually thinking is that others may be laughing at YOU after seeing your antics with your collection of ids over the last fifteen years or so.